What’s in the US Food and Drug Administration’s CBD Report to Congress?

The FDA is reopening public comment, collaborating with global regulators on how to handle cannabinoids, and backing research on CBD and “dermal penetration.”

CBD
Congress, Newsletter

In Congress, Republicans Swing Against Cannabis Rescheduling

An excerpt from the Cannabis Wire Daily newsletter.

New York

Cannabis Loyalty Programs, Discounts Could Soon Come to New York’s Legal Shops

Regulators proposed new rules to open the door to billboards, discounts, and loyalty programs – which have already shown up at some shops.